The HCT-116 CRC xenograft model was chosen for the following reasons: (i) its low FcRn level (< 2 TPM, transcript per million) [44], (ii) its KRAS mutation at G13D, (iii) its responsiveness to irinotecan. This evidence concerns the gene FCGRT and colorectal carcinoma.